Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 32.00 | |
5 mg | In stock | $ 59.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 183.00 | |
50 mg | In stock | $ 328.00 | |
100 mg | In stock | $ 497.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 89.00 |
Description | SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM). |
Targets&IC50 | JNK-JIP:239 nM , JNK:0.7 μM |
In vitro | TNF-α stimulated phosphorylation of c-Jun in HeLa cells inhibited by SU3327 with EC50 of 6.23 μM[1]. SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1[3]. |
In vivo | In male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice, SU3327 (25 mg/kg; intraperitoneal injection; ) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1]. SU3327 has favorable microsomal and plasma stability (T1/2 = 27 min)[1]. |
Synonyms | halicin |
Molecular Weight | 261.3 |
Formula | C5H3N5O2S3 |
CAS No. | 40045-50-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.5 mg/mL (239.19 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SU3327 40045-50-9 MAPK JNK Thiadiazole TNF-α Inhibitor SU 3327 inhibit p38α insulin phosphorylation substrate-competitive SU-3327 JIP protein-protein halicin PPI inhibitor